Online inquiry

IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14205MR)

This product GTTS-WQ14205MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Psoriatic arthritis (PSA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14205MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2280MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ13871MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ11320MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-524
GTTS-WQ10390MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2127399
GTTS-WQ2135MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ12157MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-009
GTTS-WQ6273MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CR-6261
GTTS-WQ9356MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW